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Rationale: AEDs are increasingly evaluated for efficacy in bipolar disorders utilizing double-blind, placebo-controlled, ran-
domized clinical trials (RCTs) as required by the FDA. However, the risk to patients is under-estimated in trial design. Bipolar
depression has a significant risk for suicide; bipolar episodes can lead to kindling with increased long-term morbidity; rapid
regression may occur during the placebo phase or during dose ranging trials with resultant active suicide status. The associated
risks mandate that the ethics of FDA-required protocols are addressed.
Method: Comparative analysis and literature review of bipolar and epilepsy research designs.
Results: In psychiatry, all INDs require RCTs for approval. In epilepsy, AEDs are initially approved as add-on agents only.
Once AEDs have demonstrated add-on efficacy, cross-over studies comparing active AEDs, sub-optimal dosing paradigms,
new-onset, and pre-surgical inpatient placebo trials are utilized to prove efficacy of the new AED in monotherapy. Ethical
considerations to avoid seizures and to minimize risks to subjects have led to newer clinical trial designs.
Conclusions: The FDA initially requires add-on studies with new AEDs due to the risk of seizures during the placebo phase. The
author argues that bipolar research warrants similar add-on studies to prove efficacy because the risk of suicide and increased
long-term morbidity in the bipolar population is as significant as the risk of seizures in the epilepsy population. Although
the number of patients needed to prove statistical efficacy would increase, the safety of such research would also markedly
increase. The author further concludes that with the risk of suicide during bipolar research, ethical considerations require
increased frequency of patient contact with a significant other co-signing the informed consent for research and serving as a
contact for the coordinator.
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INTRODUCTION
The concepts of nonmaleficence and beneficence—
to do no harm and to do good—are the cornerstones
to the ethical practice of clinical medicine1. As a
profession, we uphold these principles by practicing
accepted standards of care, by specifically avoiding
malpractice and abandonment, but most importantly
by always remembering that the patients’ interests
come first.
But how do we know what should be appropriate
care for patients with specific illnesses? How truly
do we know what will be beneficial and what
will be detrimental in different patient populations?
Herein lies the merit of scientific research. Initially,
such research is observational in nature utilizing
case studies and case series in uncontrolled patient
populations. This leads the clinician to potential
hypotheses. Ultimately, with the presence of these
hypotheses, the clinical researcher attempts to answer
the question of whether a specific intervention is in
fact an active and effective medical treatment with
maximum benefits and minimum risks.
With the bio-technical explosion of this past century,
increasing numbers of pharmaceuticals are being
evaluated for efficacy within psychiatric illnesses and
specifically for the treatment of affective disorders.
Furthermore, original theories of limited episodic
Published online 19 September 2001.
∗Presented at the 24th International Epilepsy Congress, Buenos Aires, Argentina, 14th May 2001.
†E-mail: kaufmakr@umdnj.edu
1059–1311/02/010051 + 06 $35.00/0 c© 2001 BEA Trading Ltd
52 K. R. Kaufman
illness have changed to chronic recurrence leading
to the need for long-term psychotropic prophylaxis2.
But is the efficacy of the newer agent being
determined by comparison to known effective agents,
to placebos, or as adjunctive treatment? The double-
blind, placebo-controlled, randomized trial (RCT) has
been utilized for over 50 years3 and the Food and Drug
Administration (FDA) requires such pivotal trials for
approval to market4. It has been argued that there is
a 30–40% placebo effect in psychiatric trials and as
such, unless the new agent is compared to placebo,
a comparative trial to a known efficacious agent may
be relatively meaningless5, 6. In that sense, to argue
that the newer agent is efficacious when it is not
may be doing a greater harm to the entire diagnostic
population. As such, one could argue that from a
societal perspective, there may be a greater risk not
to utilize the RCT.
Yet, is there a risk to the patient who partakes in
such study and receives only placebo? In light of the
Declaration of Helsinki, is it considered ethical or even
legal to utilize RCTs when more effective therapeutic
agents than placebo are available7, 8? A recent review
of suicide risk in patients treated with placebo during
antidepressant clinical trials revealed no significant
difference in the rates of suicide and attempted suicide
among the drug-treated and placebo-treated groups9.
However, this review only addressed the issue of
suicide during the period of the clinical trial itself;
the review did not address the effects on long-term
morbidity and mortality that may exist secondary to
having taken a placebo during an RCT.
RESEARCH IN BIPOLAR AFFECTIVE
DISORDERS
These issues are especially meaningful in research
studies applied to bipolar affective disorders. Whereas
RCTs are best suited to study homogeneous popula-
tions, patients with bipolar disorders are more often
heterogeneous (be it secondary to severity of illness,
phase of illness, cycling, illness patterns, or comor-
bidity) resulting in the need for large multicenter
studies that may not address the typical clinical bipolar
patient10. Bipolar depression carries a significant
risk for suicide attempts and actual suicides that is
increased with psychiatric comorbidity11, 12. Bipolar
episodes can be associated with kindling and increased
long-term morbidity from these disorders. Rapid
regression can occur during a placebo phase or even
with the patient on the active study agent during dose
ranging trials, with resultant active suicidal status.
The washout process associated with RCTs is very
important when addressing bipolar research. There is
a differential effect with rapid versus gradual lithium
treatment discontinuation on illness recurrence13, 14.
Thus, there is an implication on the validity associated
with bipolar research trials wherein lithium was
discontinued abruptly15. Furthermore, the dramatic
effect associated with lithium discontinuation on
suicide (a 20-fold increase in suicidal behaviors and
a 13-fold increase in mortality during the first year
off lithium) is apparently increased with rapid versus
gradual discontinuation16.
Of interest is that the majority of RCTs in treatment
of acute bipolar mania and depression used cross-
over designs that are not currently considered optimal
for discrimination between active drug and placebo
response17. In fact, there is only one parallel-group
RCT demonstrating the effectiveness of lithium over
placebo in the treatment of acute mania18; there are
two parallel-group RCTs demonstrating the effective-
ness of divalproex over placebo in the treatment of
acute mania18, 19; and there are two parallel-group
RCTs demonstrating the effectiveness of olanzapine
over placebo in the treatment of acute mania20, 21.
Furthermore, there is only one positive parallel-group
monotherapy RCT demonstrating the effectiveness of
a proposed mood stabilizer, lamotrigine, over placebo
in the treatment of acute bipolar depression22.
In a review of seven maintenance bipolar parallel-
group RCTs, five lithium studies were done in the
early 1970s when the effects of abrupt discontinu-
ation of lithium on illness recurrence were not yet
appreciated, and one carbamazepine study used liberal
adjunctive medications that obscured the relapse
rates between placebo and active agent23. Only one
study, a recent comparison of divalproex to lithium
to placebo incorporated DSM-III-R criteria, rational
interventions during the first month to address the
effects of discontinuing open-label treatment, and
survival analysis23, 24. However, that study showed no
statistical difference in the primary outcome measure,
time to recurrence of any mood episode24.
Thus, not only are there significant bioethical
issues that must be addressed when preparing bipolar
research designs but also one must be cognizant that
there are very few positive parallel-group RCTs that
have been done in the bipolar population. There are
both societal obligations to approve the most effective
agent and individual obligations to do no harm during
an RCT in addition to the requirement that there be
no long-term morbidity and mortality secondary to
having participated in a placebo arm of an RCT.
EVALUATION OF ANTIEPILEPTIC DRUGS
(AEDS)
In light of the new wave of anticonvulsant usage in the
treatment of bipolar disorders, it was felt appropriate
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to look at the research designs currently used in
recent AEDs being approved for the treatment of
epilepsy as a starting point for re-evaluation of bipolar
research.
Specifically, although the parallel-group RCT is
considered the gold standard for proving efficacy,
ethical considerations in patients with epilepsy have
led to the initial evaluation of the study AED in
adjunctive therapy25. During the past decade, there
have been a series of new AEDs evaluated in this
way: gabapentin, lamotrigine, tiagabine, topiramate,
zonisamide, vigabatrin, oxcarbazepine, levetiracetam,
and felbamate26–35.
In a meta analysis of 29 add-on studies representing
4091 randomized patients on gabapentin, lamotrigine,
tiagabine, topiramate, vigabatrin, and zonisamide it
was noted that all six AEDs were more effective
than placebo; however, the rate of efficacy of the
investigated AEDs had a two-fold difference between
most effective and least effective and the rate of
discontinuation from studies had a four-fold differ-
ence. As such, comparative randomized controlled
trials were felt to be indicated to allow an evidenced
based choice between these drugs36. In summary, the
add-on studies satisfied registration requirements for
adjunctive AED therapy, but these studies were not felt
to give the clinician the needed information to make
rational treatment decisions as would be garnered from
comparative monotherapy trials37.
In the AED add-on studies, there are no ethi-
cal dilemmas, for the patient remains on an ac-
tive agent. Furthermore, well-designed multicenter
placebo-controlled RCTs result in ready registration
of adjunctive AED therapy. However, as noted above,
the data obtained does not allow for clear comparisons
among AEDs. Also, in add-on studies the potential
for pharmacokinetic interactions that might influence
outcomes of studies must be addressed38, 39.
With the registration of an AED for adjunctive ther-
apy, there would be decreased ethical considerations
for use in comparative monotherapy trials. But as
different regulatory bodies have different parameters
for registration of AEDs for monotherapy, compara-
tive efficacy studies may not be accepted; specifically,
European agencies often accept comparative efficacy
whereas the FDA requires documented superiority of
the investigational AED25, 40. Yet it is in the direct
comparative trials that the clinician may find the most
useful data: lack of drug interactions that may obscure
findings, treatment similar to that which would be
found in the clinic, and the desired evidenced-based
comparison of one known efficacious AED to the
newer investigated AED.
Thus it is necessary to pursue parallel-group
placebo-controlled AED monotherapy RCTs. In such
trials, the purest answer to efficacy can be obtained
while avoiding pharmacokinetic drug interactions.
However, now the ethical dilemma/justification of
having a refractory patient off active medication
must be considered. There are two designs that have
often been utilized to approach this problem: (a)
high-dose/low-dose active control monotherapy41–43
and (b) pre-surgical evaluation placebo-controlled
monotherapy25, 44–46. There are ethical differences
between the two approaches. When a suboptimal
active medication is used as a control, the patient is
not receiving normal antiepileptic treatment and as a
pseudo-comparative study, the patient may be unaware
that the suboptimal treatment arm may be subther-
apeutic for that individual patient. When queried
as to why this study design is utilized, researchers
have argued that with low dosage divalproex as the
active control generalized tonic–clonic seizures will be
blocked while still allowing auras and partial seizures
to occur. However, this may not be the case with all
study patients nor would it necessarily be the case
were alternative suboptimal AEDs to be utilized47. To
permit such studies to be done, very specific informed
consents explaining the role of the low-dose active
control would be required. In presurgical evaluation
placebo-controlled monotherapy there is a rationale
for the patient being on placebo—the need to be
thoroughly evaluated for a surgical intervention. Yet,
once video monitoring has identified the focus, is
it ethical to keep the patient off a known effective
AED? This design presents the cleanest approach in
an inpatient setting with fixed and easily monitored
exit criteria. In both designs the emphasis should
be placed upon limiting total time in study and
utilizing a combination of fixed number of seizures,
percentage seizure frequency increase, and severity of
seizures (serial seizures or status) as strict criteria in
order to maximize the benefits from the study while
minimizing the potential adverse effects to the study
patient. With the introduction of preset exit criteria
based on seizure activity, researchers have argued that
ethical considerations in these two study designs are
minimized48, 49.
These novel monotherapy trial designs lead to
registration of the investigated AED for monotherapy;
but these trials do not tell the clinician which
AED to utilize. For this, one requires comparative
monotherapy trials with optimal doses of standard
AEDs37. Some argue that significant ethical questions
remain with these monotherapy trial designs and
that the gold standard in AED evaluation should be
randomized, long-term comparative trials50.
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DISCUSSION
In psychiatry, all investigational new drugs (INDs)
require RCTs. To date, no psychotropics have been
registered as adjunctive agents only. In the treatment
of epilepsy, AEDs are initially approved as add-
on agents after undergoing parallel-group placebo-
controlled RCTs. Once AEDs have demonstrated
efficacy as add-on agents, novel monotherapy trials
including suboptimal dosing paradigms (low-dose
active control) and presurgical inpatient placebo trials
are utilized to prove the efficacy of the new agent in
monotherapy followed by comparative monotherapy
trials against optimal doses of standard AEDs.
Nonetheless, ethical issues exist in epilepsy research
just as in bipolar research: should the IND be tested
against a placebo and will there be harm to the
patient under such circumstances; specifically, is the
risk/benefit ratio too great to allow placebo controls.
The new monotherapy AED trial designs were
created in order to minimize ethical concerns while
maximizing assessment of efficacy. Unfortunately, in
any clinical study that involves placebo controls there
will always be an inherent risk; similarly with the use
of a low-dose active control the issue of the pseudo-
comparative trial must be considered. It is true that
even with low serum concentrations of standard AEDs
there can be some anticonvulsant effect, but it may
not be generalizable to the entire study group and the
study patients need to clearly appreciate that from a
well-crafted informed consent. But the critical change
in the newer AED monotherapy designs is strict exit
criteria based on seizure activity. What can bipolar
research learn from AED development and especially
from these newer AED designs?
There is a glaring need for parallel-group placebo-
controlled add-on RCTs in bipolar research. Such
trials could be performed in either inpatient or
outpatient settings. With such design, the ethical
dilemmas faced by pure placebo trials would be
obviated, for all patients would remain on active
agents with one arm receiving the study agent and
the other placebo. Furthermore, although the add-
on study may be more expensive, secondary to
the presumed need for a greater N to power the
study, enrollment into such study should be much
easier. Based on the outcome of these add-on trials,
enrichment continuation (maintenance) studies could
be designed10, 51. With the knowledge that the study
agent is effective in adjunctive treatment of bipolar
disorders, the ethical concerns in further acute and
maintenance comparative studies would be decreased.
Nonetheless, the FDA still requires the placebo-
controlled RCT for registration of psychotropics.
How then to pursue such studies while minimizing
patient risk? Taking a lesson from the presurgical
evaluation AED trials, the effective bipolar adjunctive
agent should be studied in acute hospitalized patients
where the greatest change would be noted in the
shortest time period while permitting the greatest
safety for the study patients. In such parallel-group
placebo-controlled RCTs, there must be multiple
outcome measures utilized with strict exit criteria
if there are any signs of a worsening in illness
status in addition to the presence of rational rescue
medications.
In addition, rapid cycling and ultra rapid cycling
patients should be studied. Although these patients
are often refractory to treatment, the severity and
frequency of symptoms should permit an easier
discrimination between the efficacy of placebo and
study agent10.
Inpatient settings would be appropriate for manic
episodes and for severe depression with active
suicidal ideation; however, not all bipolar patients that
need to be studied would be so severely ill. How
would one study hypomanic or moderately depressed
bipolar patients without suicidal ideation, especially
in outpatient maintenance trials? There are several
concerns with outpatient studies: is the patient too
ill to participate in such a study (i.e. too suicidal);
does the patient truly understand the risks involved
and as such is the consent an informed consent; does
the consent clearly explore long-term consequences of
being in an RCT (including the potential for long-term
morbidity and mortality for having been in the placebo
arm of the RCT); is there sufficient supervision of this
patient in the outpatient setting; are there appropriate
exit criteria. For these reasons, there should be tight
inclusion/exclusion criteria with specific emphasis
placed on suicidal ideation. Furthermore, in bipolar
disorders where the risk of suicide attempt is so great,
a significant other should witness the consent and
agree to be the independent contact to the study team
regarding any regression between study visits. Finally,
the frequency of study visits should be increased.
Perhaps the most important steps to be taken
concern the methodology of assessing treatment
responses. For example, in the lamotrigine study
for bipolar depression the Montgomery–Asberg De-
pression Rating Scale (MADRS) appeared to be
more sensitive than the Hamilton Depression Rating
Scale (HAMDRS) in discriminating response from
placebo17, 22. Thus multiple outcome measures and
survival analysis should be included23, 52. Further-
more, it has been suggested that the Life Chart
Method (LCM) is utilized as a rating instrument
to measure severity of episodes and subsyndromal
symptoms23, 52, 53.
As noted in the epilepsy literature, comparative
studies are most needed in order to allow evidenced-
based clinical decisions between medications. In
Comparative bioethics 55
bipolar research, the Stanley Foundation Bipolar
Treatment Outcome Network monitors the continuous
daily longitudinal follow-up of >500 outpatients and
enrolls these patients in open-label add-on, placebo-
controlled add-on, and randomized active comparator
add-on studies in the presence of existing mood
stabilizers resulting in significant clinical findings
while minimizing any patient risks10, 54–57.
There are many similarities between AED and
bipolar research—both in trial designs and in ethical
dilemmas. That both epileptologists and psychiatrists
are addressing these issues is noteworthy. It is
expected that these issues will be revisited frequently.
As a template, seven requirements for clinical ethical
research have been proposed: value, scientific validity,
fair subject selection, favorable risk-benefit ratio,
independent review, informed consent, and respect for
potential and enrolled subjects58. These should be
adhered to as further research designs are created.
Although research is performed in order to improve
clinical insight into treating the diagnostic category,
the individual and the individual’s rights must never
be forgotten59.
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